Selected research
Industry Growth & Trends
Global Cyproheptadine Industry Growth and Trends Forecast to 2032
Market perspective
The global Cyproheptadine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Cyproheptadine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Cyproheptadine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cyproheptadine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Cyproheptadine include MSD, Abbott, Teva, Novartis, Teriak, Royal Pharma, Qualipharm, Pharma Arte and Panbiotic Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Cyproheptadine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Cyproheptadine market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cyproheptadine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cyproheptadine.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Cyproheptadine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Cyproheptadine Market by Company
MSD
Abbott
Teva
Novartis
Teriak
Royal Pharma
Qualipharm
Pharma Arte
Panbiotic Laboratories
Nichi-Iko Pharmaceutical
Medphano
Laboratoires Servier
Kalbe
General Pharma
Fu Yuan Pharmaceutical
Faes Pharma
Cipla Medpro South Africa
Caillon and Hamonet
Arena Pharmaceuticals
Apex Pharma
Allena Pharmaceuticals
Aero-Chem
Cyproheptadine Segment by Type
Patent
Generic
Cyproheptadine Segment by Application
On-line
Drug Store
Hospital
Cyproheptadine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cyproheptadine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cyproheptadine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cyproheptadine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cyproheptadine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Cyproheptadine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Patent
- Generic
Applications
- On-line
- Drug Store
- Hospital
Companies covered
- MSD
- Abbott
- Teva
- Novartis
- Teriak
- Royal Pharma
- Qualipharm
- Pharma Arte
- Panbiotic Laboratories
- Nichi-Iko Pharmaceutical
- Medphano
- Laboratoires Servier
- Kalbe
- General Pharma
- Fu Yuan Pharmaceutical
- Faes Pharma
- Cipla Medpro South Africa
- Caillon and Hamonet
- Arena Pharmaceuticals
- Apex Pharma
- Allena Pharmaceuticals
- Aero-Chem
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Cyproheptadine Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Cyproheptadine Sales Estimates and Forecasts (2021-2032)
- 1.3 Cyproheptadine Market by Type
- 1.3.1 Patent
- 1.3.2 Generic
- 1.4 Global Cyproheptadine Market Size by Type
- 1.4.1 Global Cyproheptadine Market Size Overview by Type (2021-2032)
- 1.4.2 Global Cyproheptadine Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Cyproheptadine Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Cyproheptadine Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Cyproheptadine Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Cyproheptadine Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Cyproheptadine Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Cyproheptadine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Cyproheptadine Industry Trends
- 2.2 Cyproheptadine Industry Drivers
- 2.3 Cyproheptadine Industry Opportunities and Challenges
- 2.4 Cyproheptadine Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Cyproheptadine Revenue (2021-2026)
- 3.2 Global Top Players by Cyproheptadine Sales (2021-2026)
- 3.3 Global Top Players by Cyproheptadine Price (2021-2026)
- 3.4 Global Cyproheptadine Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Cyproheptadine Major Company Production Sites & Headquarters
- 3.6 Global Cyproheptadine Company, Product Type & Application
- 3.7 Global Cyproheptadine Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Cyproheptadine Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Cyproheptadine Players Market Share by Revenue in 2025
- 3.8.3 2025 Cyproheptadine Tier 1, Tier 2, and Tier 3
4 Cyproheptadine Regional Status and Outlook
- 4.1 Global Cyproheptadine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Cyproheptadine Historic Market Size by Region
- 4.2.1 Global Cyproheptadine Sales in Volume by Region (2021-2026)
- 4.2.2 Global Cyproheptadine Sales in Value by Region (2021-2026)
- 4.2.3 Global Cyproheptadine Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Cyproheptadine Forecasted Market Size by Region
- 4.3.1 Global Cyproheptadine Sales in Volume by Region (2027-2032)
- 4.3.2 Global Cyproheptadine Sales in Value by Region (2027-2032)
- 4.3.3 Global Cyproheptadine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Cyproheptadine by Application
- 5.1 Cyproheptadine Market by Application
- 5.1.1 On-line
- 5.1.2 Drug Store
- 5.1.3 Hospital
- 5.2 Global Cyproheptadine Market Size by Application
- 5.2.1 Global Cyproheptadine Market Size Overview by Application (2021-2032)
- 5.2.2 Global Cyproheptadine Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Cyproheptadine Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Cyproheptadine Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Cyproheptadine Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Cyproheptadine Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Cyproheptadine Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Cyproheptadine Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 MSD
- 6.1.1 MSD Company Information
- 6.1.2 MSD Business Overview
- 6.1.3 MSD Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 MSD Cyproheptadine Product Portfolio
- 6.1.5 MSD Recent Developments
- 6.2 Abbott
- 6.2.1 Abbott Company Information
- 6.2.2 Abbott Business Overview
- 6.2.3 Abbott Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Abbott Cyproheptadine Product Portfolio
- 6.2.5 Abbott Recent Developments
- 6.3 Teva
- 6.3.1 Teva Company Information
- 6.3.2 Teva Business Overview
- 6.3.3 Teva Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Teva Cyproheptadine Product Portfolio
- 6.3.5 Teva Recent Developments
- 6.4 Novartis
- 6.4.1 Novartis Company Information
- 6.4.2 Novartis Business Overview
- 6.4.3 Novartis Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Novartis Cyproheptadine Product Portfolio
- 6.4.5 Novartis Recent Developments
- 6.5 Teriak
- 6.5.1 Teriak Company Information
- 6.5.2 Teriak Business Overview
- 6.5.3 Teriak Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Teriak Cyproheptadine Product Portfolio
- 6.5.5 Teriak Recent Developments
- 6.6 Royal Pharma
- 6.6.1 Royal Pharma Company Information
- 6.6.2 Royal Pharma Business Overview
- 6.6.3 Royal Pharma Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Royal Pharma Cyproheptadine Product Portfolio
- 6.6.5 Royal Pharma Recent Developments
- 6.7 Qualipharm
- 6.7.1 Qualipharm Company Information
- 6.7.2 Qualipharm Business Overview
- 6.7.3 Qualipharm Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 Qualipharm Cyproheptadine Product Portfolio
- 6.7.5 Qualipharm Recent Developments
- 6.8 Pharma Arte
- 6.8.1 Pharma Arte Company Information
- 6.8.2 Pharma Arte Business Overview
- 6.8.3 Pharma Arte Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 Pharma Arte Cyproheptadine Product Portfolio
- 6.8.5 Pharma Arte Recent Developments
- 6.9 Panbiotic Laboratories
- 6.9.1 Panbiotic Laboratories Company Information
- 6.9.2 Panbiotic Laboratories Business Overview
- 6.9.3 Panbiotic Laboratories Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 Panbiotic Laboratories Cyproheptadine Product Portfolio
- 6.9.5 Panbiotic Laboratories Recent Developments
- 6.10 Nichi-Iko Pharmaceutical
- 6.10.1 Nichi-Iko Pharmaceutical Company Information
- 6.10.2 Nichi-Iko Pharmaceutical Business Overview
- 6.10.3 Nichi-Iko Pharmaceutical Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.10.4 Nichi-Iko Pharmaceutical Cyproheptadine Product Portfolio
- 6.10.5 Nichi-Iko Pharmaceutical Recent Developments
- 6.11 Medphano
- 6.11.1 Medphano Company Information
- 6.11.2 Medphano Business Overview
- 6.11.3 Medphano Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.11.4 Medphano Cyproheptadine Product Portfolio
- 6.11.5 Medphano Recent Developments
- 6.12 Laboratoires Servier
- 6.12.1 Laboratoires Servier Company Information
- 6.12.2 Laboratoires Servier Business Overview
- 6.12.3 Laboratoires Servier Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.12.4 Laboratoires Servier Cyproheptadine Product Portfolio
- 6.12.5 Laboratoires Servier Recent Developments
- 6.13 Kalbe
- 6.13.1 Kalbe Company Information
- 6.13.2 Kalbe Business Overview
- 6.13.3 Kalbe Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.13.4 Kalbe Cyproheptadine Product Portfolio
- 6.13.5 Kalbe Recent Developments
- 6.14 General Pharma
- 6.14.1 General Pharma Company Information
- 6.14.2 General Pharma Business Overview
- 6.14.3 General Pharma Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.14.4 General Pharma Cyproheptadine Product Portfolio
- 6.14.5 General Pharma Recent Developments
- 6.15 Fu Yuan Pharmaceutical
- 6.15.1 Fu Yuan Pharmaceutical Company Information
- 6.15.2 Fu Yuan Pharmaceutical Business Overview
- 6.15.3 Fu Yuan Pharmaceutical Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.15.4 Fu Yuan Pharmaceutical Cyproheptadine Product Portfolio
- 6.15.5 Fu Yuan Pharmaceutical Recent Developments
- 6.16 Faes Pharma
- 6.16.1 Faes Pharma Company Information
- 6.16.2 Faes Pharma Business Overview
- 6.16.3 Faes Pharma Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.16.4 Faes Pharma Cyproheptadine Product Portfolio
- 6.16.5 Faes Pharma Recent Developments
- 6.17 Cipla Medpro South Africa
- 6.17.1 Cipla Medpro South Africa Company Information
- 6.17.2 Cipla Medpro South Africa Business Overview
- 6.17.3 Cipla Medpro South Africa Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.17.4 Cipla Medpro South Africa Cyproheptadine Product Portfolio
- 6.17.5 Cipla Medpro South Africa Recent Developments
- 6.18 Caillon and Hamonet
- 6.18.1 Caillon and Hamonet Company Information
- 6.18.2 Caillon and Hamonet Business Overview
- 6.18.3 Caillon and Hamonet Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.18.4 Caillon and Hamonet Cyproheptadine Product Portfolio
- 6.18.5 Caillon and Hamonet Recent Developments
- 6.19 Arena Pharmaceuticals
- 6.19.1 Arena Pharmaceuticals Company Information
- 6.19.2 Arena Pharmaceuticals Business Overview
- 6.19.3 Arena Pharmaceuticals Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.19.4 Arena Pharmaceuticals Cyproheptadine Product Portfolio
- 6.19.5 Arena Pharmaceuticals Recent Developments
- 6.20 Apex Pharma
- 6.20.1 Apex Pharma Company Information
- 6.20.2 Apex Pharma Business Overview
- 6.20.3 Apex Pharma Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.20.4 Apex Pharma Cyproheptadine Product Portfolio
- 6.20.5 Apex Pharma Recent Developments
- 6.21 Allena Pharmaceuticals
- 6.21.1 Allena Pharmaceuticals Company Information
- 6.21.2 Allena Pharmaceuticals Business Overview
- 6.21.3 Allena Pharmaceuticals Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.21.4 Allena Pharmaceuticals Cyproheptadine Product Portfolio
- 6.21.5 Allena Pharmaceuticals Recent Developments
- 6.22 Aero-Chem
- 6.22.1 Aero-Chem Company Information
- 6.22.2 Aero-Chem Business Overview
- 6.22.3 Aero-Chem Cyproheptadine Sales, Revenue and Gross Margin (2021-2026)
- 6.22.4 Aero-Chem Cyproheptadine Product Portfolio
- 6.22.5 Aero-Chem Recent Developments
7 North America by Country
- 7.1 North America Cyproheptadine Sales by Country
- 7.1.1 North America Cyproheptadine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Cyproheptadine Sales by Country (2021-2026)
- 7.1.3 North America Cyproheptadine Sales Forecast by Country (2027-2032)
- 7.2 North America Cyproheptadine Market Size by Country
- 7.2.1 North America Cyproheptadine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Cyproheptadine Market Size by Country (2021-2026)
- 7.2.3 North America Cyproheptadine Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Cyproheptadine Sales by Country
- 8.1.1 Europe Cyproheptadine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Cyproheptadine Sales by Country (2021-2026)
- 8.1.3 Europe Cyproheptadine Sales Forecast by Country (2027-2032)
- 8.2 Europe Cyproheptadine Market Size by Country
- 8.2.1 Europe Cyproheptadine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Cyproheptadine Market Size by Country (2021-2026)
- 8.2.3 Europe Cyproheptadine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Cyproheptadine Sales by Country
- 9.1.1 Asia-Pacific Cyproheptadine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Cyproheptadine Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Cyproheptadine Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Cyproheptadine Market Size by Country
- 9.2.1 Asia-Pacific Cyproheptadine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Cyproheptadine Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Cyproheptadine Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Cyproheptadine Sales by Country
- 10.1.1 South America Cyproheptadine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Cyproheptadine Sales by Country (2021-2026)
- 10.1.3 South America Cyproheptadine Sales Forecast by Country (2027-2032)
- 10.2 South America Cyproheptadine Market Size by Country
- 10.2.1 South America Cyproheptadine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Cyproheptadine Market Size by Country (2021-2026)
- 10.2.3 South America Cyproheptadine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Cyproheptadine Sales by Country
- 11.1.1 Middle East and Africa Cyproheptadine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Cyproheptadine Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Cyproheptadine Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Cyproheptadine Market Size by Country
- 11.2.1 Middle East and Africa Cyproheptadine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Cyproheptadine Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Cyproheptadine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Cyproheptadine Value Chain Analysis
- 12.1.1 Cyproheptadine Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Cyproheptadine Production Mode & Process
- 12.2 Cyproheptadine Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Cyproheptadine Distributors
- 12.2.3 Cyproheptadine Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst